These therapies have demonstrated success in preclinical models for other ALS subtypes, like SOD1 and C9orf72, and efforts to develop similar approaches for VAPB-related ALS8 are in the early stages [5,32]. Here, SOD1 is linked to amyotrophic lateral sclerosis.